HCW Biologics says TGF-β trap-IL-15 fusion expands CD8+ T, NK cells in human studies
PUBT · 3d ago
Share
Listen to the news
- HCW Biologics highlighted human data showing its TGF-β trap–IL-15 fusion expanded progenitor CD8+ T cells and NK cells.
- Program reported clinical benefit in cancer patients, with the fusion described as well tolerated.
- Preclinical work showed activity in models of HIV-1 and bronchopulmonary dysplasia.
- Second-generation pipeline now embeds the TGF-β/IL-15 moiety into TRBC-based TCE and ICI constructs.
- Lead candidates HCW11-018b and HCW11-040 are IND-enabling, with first clinical studies planned for 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608250900PRIMZONEFULLFEED9815252) on August 25, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending